Private Capital Management Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,800 shares of the biopharmaceutical company’s stock after selling 5,400 shares during the period. Pfizer accounts for approximately 1.4% of Private Capital Management Inc.’s portfolio, making the stock its 5th largest position. Private Capital Management Inc.’s holdings in Pfizer were worth $1,401,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale increased its position in shares of Pfizer by 3.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 4,540,506 shares of the biopharmaceutical company’s stock valued at $159,023,000 after buying an additional 141,247 shares in the last quarter. Bancorpsouth Inc. boosted its stake in Pfizer by 2.1% in the second quarter. Bancorpsouth Inc. now owns 71,479 shares of the biopharmaceutical company’s stock valued at $2,516,000 after buying an additional 1,468 shares during the last quarter. Reynders McVeigh Capital Management LLC boosted its stake in Pfizer by 10.2% in the second quarter. Reynders McVeigh Capital Management LLC now owns 53,372 shares of the biopharmaceutical company’s stock valued at $1,879,000 after buying an additional 4,945 shares during the last quarter. Chickasaw Capital Management LLC bought a new stake in Pfizer during the second quarter valued at $235,000. Finally, Mogy Joel R Investment Counsel Inc. boosted its stake in Pfizer by 1.9% in the second quarter. Mogy Joel R Investment Counsel Inc. now owns 141,804 shares of the biopharmaceutical company’s stock valued at $4,993,000 after buying an additional 2,675 shares during the last quarter. 69.65% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.5352% on Friday, hitting $33.4699. The stock had a trading volume of 8,412,975 shares. The company has a 50 day moving average price of $34.33 and a 200-day moving average price of $34.17. The company has a market cap of $203.02 billion, a price-to-earnings ratio of 29.6719 and a beta of 0.86. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same quarter in the prior year, the firm earned $0.56 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.57%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
PFE has been the subject of several research reports. Jefferies Group lowered their price objective on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, June 20th. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a research report on Wednesday, June 15th. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price objective for the company. in a research report on Tuesday, June 28th. Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Finally, JPMorgan Chase & Co. set a $40.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.